TipRanks
Go Ultimate55% OFF

Swiss Re (SR9A) AI Stock Analysis

DE:SR9A

Swiss Re

(Frankfurt:SR9A)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Capital StrengthA group SST ~264% provides a durable regulatory and economic capital buffer, enabling Swiss Re to absorb large catastrophe losses, sustain underwriting discipline, continue buybacks and subordinated issuance, and support client commitments over the next several quarters without forcing asset sales or panic underwriting.
Negative Factors
Declining New-Business CSMMaterial declines in new‑business CSM across segments signal weaker new‑contract profitability and lower future revenue releases. Persistently reduced CSM inflows can constrain medium‑term earnings growth and limit the company's ability to replace favorable legacy margins, making future earnings more dependent on reserve actions or investments.

Swiss Re (SR9A) vs. iShares MSCI Germany ETF (EWG)

-20%-15%-10%-5%0%5%10%15%DE:SR9A+7.39%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 54.81B
Dividend Yield
4.16%
Average Volume (3M)
52
Price to Earnings (P/E)
11.2
Beta (1Y)
0.46
Revenue Growth
-9.90%
EPS Growth
22.25%
Country
Germany
Employees
14,893
Sector
Financial
Sector Strength
68
Industry
Insurance - Reinsurance

Swiss Re Business Overview & Revenue Model

Company Description

Swiss Re AG, along with its various group entities, provides a comprehensive suite of services globally, including extensive wholesale reinsurance, direct insurance offerings, and other innovative methods for risk transfer, complemented by associated...

Swiss Re Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:13.56%|Next Earnings Date:Nov 04, 2026
Earnings Call SentimentPositive

The call presented a predominantly positive operational and financial picture: strong H1 net income (USD 2.8B), high ROE (23%), robust P&C combined ratio (76.7%), solid Life & Health Re results, healthy investment returns (4.0% ROI) and a very strong capital position (SST ~264%). Management also announced an increased cost-reduction target and continued active capital return (buyback). Offsetting risks include notable declines in new business CSM across segments, pricing pressure in specific lines (non-proportional property, parts of Specialty, Corporate rates), rising P&C expense ratio, and questions about the sustainability of large short-tail reserve releases. Overall, the positives (underwriting results, capital, investments, cost discipline) materially outweigh the headwinds related to new-business profitability and selective pricing pressure, but the latter warrant monitoring going into 2027.

Positive Updates

Strong Net Income and Capital Position
Reported net income of USD 2.8 billion for H1 2026 (more than 60% of the full-year target of USD 4.5 billion) and an estimated group SST ratio of 264% (up 14 percentage points since Jan 1, 2026), indicating a very strong capital position.

Negative Updates

Decline in New Business CSM Across Segments
New business CSM reductions year-on-year: P&C Re USD 1.6B vs USD 2.2B (down ~27%), Corporate Solutions USD 201M vs USD 262M (down ~23%), Life & Health Re USD 338M vs USD 569M (down ~41%), reflecting lower transaction activity and a more challenging new-business environment.

Company Guidance

Management reiterated a full‑year net income target of USD 4.5bn (H1 net income USD 2.8bn, >60% of target) and highlighted strong H1 metrics — group ROE 23% — while setting specific business targets and near‑term expectations: Life & Health H1 net income just over USD 1.0bn with a 2026 net income target of USD 1.7bn, an insurance service result of USD 1.2bn and a CSM release of USD 758m (annualized ~9%); P&C Re H1 insurance service result USD 1.8bn, combined ratio 76.7% (full‑year target <85%), new business CSM USD 1.6bn (vs USD 2.2bn prior) and USD 6–7bn of treaty renewals to end‑June; Corporate Solutions H1 combined ratio 86.1%, insurance service result USD 578m, CSM release ~USD 400m and new business CSM USD 201m (vs USD 262m prior); midyear renewals showed 11% volume growth and year‑to‑date premium volume +0.5% with nominal pricing broadly flat (casualty mid‑single‑digit increases, non‑prop property down high single digits), year‑to‑date loss assumptions +4.4% (explaining a ~4.6% risk‑adjusted price decline), investment ROI 4.0% with recurring income USD 2bn, estimated group SST 264% (up 14pp since Jan, ~5pp temporary benefit), ~60% of a USD 1.5bn buyback executed, an increased operating cost‑saving target of USD 500m by 2028 (run‑rate, reflected in FY2029), and management expects mid‑triple‑digit reserve releases to help offset renewal headwinds.

Swiss Re Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:SR9A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ACGLACGL83Outperform$36.29B8.5918.35%―-5.29%14.08%
RGARGA78Outperform$17.29B11.5011.29%1.42%19.54%97.85%
RNRRNR76Outperform$13.71B9.6614.82%0.48%-21.18%-3.27%
SPNTSPNT76Outperform$3.01B6.2421.84%―22.55%371.77%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
EGEG65Neutral$15.76B8.7512.52%1.95%-8.72%250.85%

* Financial Sector Average

Performance Comparison

0%20%40%DE:SR9AACGLEGRGARNRSPNTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:SR9A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:SR9ASwiss Re AG40.202.185.74%
ACGLArch Capital106.3620.3623.67%
EGEverest Group, Ltd.410.97104.9534.30%
RGAReinsurance Group Of America264.7386.3348.39%
RNRRenaissancere339.3284.7333.28%
SPNTSiriuspoint Ltd25.887.0037.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.